Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
13.10
-0.15 (-1.13%)
At close: Aug 8, 2025, 4:00 PM
12.95
-0.15 (-1.15%)
After-hours: Aug 8, 2025, 7:55 PM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts that cover Verve Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $27.75, which forecasts a 111.83% increase in the stock price over the next year. The lowest target is $22 and the highest is $35.
Price Target: $27.75 (+111.83%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 3 | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 6 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +129.01% | Jul 18, 2025 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +67.94% | Jul 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $47 → $35 | Strong Buy | Maintains | $47 → $35 | +167.18% | May 14, 2025 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +67.94% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $47 | Strong Buy | Reiterates | $47 | +258.78% | Mar 19, 2025 |
Financial Forecast
Revenue This Year
186.11M
from 36.56M
Increased by 409.12%
Revenue Next Year
29.99M
from 186.11M
Decreased by -83.89%
EPS This Year
0.06
from -1.65
EPS Next Year
-2.83
from 0.06
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 223.7M | 73.5M | 110.3M | ||
| Avg | 186.1M | 30.0M | 48.2M | ||
| Low | 159.8M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 511.8% | -60.5% | 267.6% | ||
| Avg | 409.1% | -83.9% | 60.7% | ||
| Low | 337.2% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.89 | -1.73 | -0.60 | ||
| Avg | 0.06 | -2.83 | -2.28 | ||
| Low | -1.27 | -3.48 | -3.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.